GlassScriptPhysician profile
Kathleen E Flaherty
NPI 1265755565
$3,051.05
in general payments reported to CMS, 2019-2025
30 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $338 · 2023: $1,439 · 2024: $238 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Travel and Lodging: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.56 |
| Travel and Lodging | $617.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.86 | 2021-2025 | |
| Livanova USA, INC. | $993.66 | 2023 | Vns Therapy |
| Upsher-Smith Laboratories LLC | $102.25 | 2021-2022 | |
| Pfizer INC. | $96.27 | 2023-2025 | |
| Amgen INC. | $94.47 | 2021-2023 | Aimovig |
| Ucb, INC. | $82.43 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $74.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.08 | 2021 | |
| Acadia Pharmaceuticals INC | $53.46 | 2022-2025 | Nuplazid |
| Biogen, INC. | $43.50 | 2023-2025 | Leqembi, Vumerity, Plegridy |
| Lilly USA, LLC | $39.96 | 2025 | Kisunla, Amyvid |
| Emd Serono, INC. | $36.22 | 2023-2025 | Mavenclad |
| Janssen Pharmaceuticals, INC | $30.02 | 2023 | Ponvory |
| Argenx US, INC. | $27.89 | 2025 | Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $27.45 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $27.04 | 2021 | |
| Sumitomo Pharma America, INC. | $26.75 | 2024 | Aptiom |
| Janssen Biotech, INC. | $19.50 | 2025 | |
| Banner Life Sciences, LLC | $19.35 | 2023 | |
| Grifols USA, LLC | $19.01 | 2023 | Gamunex-C |
| Octapharma USA, INC. | $17.64 | 2023 | Panzyga |
| Eisai INC. | $16.91 | 2022 | |
| Neurelis, INC. | $16.90 | 2021 | |
| Celgene Corporation | $15.91 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.22 | 2022 | |
| Ge Healthcare | $14.26 | 2023 | |
| Acorda Therapeutics, INC | $14.03 | 2021 | |
| Avion Pharmaceuticals | $13.44 | 2023 | Dhivy |
| Almatica Pharma LLC | $12.66 | 2021 | |
| Adamas Pharmaceuticals, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.